{
  "id": 19750320,
  "title": "Stock in focus: Bayer celebrates stock exchange mathematics that shareholders should know",
  "url": "https://urgent.news/2026/11/13/aktie-im-blick-bayer-zelebriert-borsen-mathematik-die-aktionare",
  "topic": "business",
  "section": "Business",
  "published": "2026-11-13T03:00:00.000Z",
  "source": {
    "name": "Handelsblatt",
    "slug": "handelsblatt",
    "url": "https://www.handelsblatt.com/finanzen/anlagestrategie/kolumnen/bayer-boersen-mathematik-die-aktionaere-kennen-sollten/100268854.html"
  },
  "original_language": "de",
  "account": "Düsseldorf: Bayer's stock is poised to be a major winner in 2026, with the potential for over 100% growth over the past year. The company's share price has nearly tripled since early 2025 and is currently near its all-time high. Despite this, Bayer remains far from its peak, which was reached in April 2015 when investors paid up to 145.80 Euros per share. That was when the life-science company was Germany's most valuable concern. The acquisition of Monsanto, an American seed and pesticide producer, for 63 billion dollars in 2018 was intended to create a global giant but instead led to a toxic situation. The company's stock plummeted almost 87% to 18.85 Euros in the following decade, primarily due to widespread lawsuits over Monsanto's herbicide glyphosate in the United States. While the stock has since recovered more than 200%, it still falls short of the previous peak by nearly 160%.",
  "summary": "After a costly poison pill acquired a good decade ago, there is a lot of good news from the life science group. But it's still a long way to old record highs.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}